At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers want to see how well botensilimab and balstilimab immunotherapy works in people who were treated for colorectal cancer. The people in this study were diagnosed with either colon cancer or colorectal liver metastases (cancer that spread to the liver). 
- A Phase 1 Study of NT-175 in People With Advanced Solid Tumors
Full Title An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
Purpose
Researchers want to find the best dose of NT-175 in people with advanced solid tumors. The people in this study have cancers that are inoperable (cannot be surgically removed) or metastatic (have spread). The types of tumors include:
- Non-small cell lung cancer
- Colorectal cancer
- Head and neck squamous cell carcinoma
- Pancreatic cancer
- Ovarian cancer
- Breast cancer
In addition, the cancers have a mutation (change) in the TP53 R175H gene. The study participants also have a molecule called HLA-A*02:01 on their cells.
NT-175 is made in a laboratory using your collected white blood cells (T cells). The T cells in NT-175 have been genetically changed so they target cells with mutated TP53 R175H. NT-175 is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have an inoperable or metastatic solid tumor with a mutated TP53 R175H gene.
- Be positive for HLA-A*02:01.
- Have cancer that keeps growing after treatment.
- Have completed prior anti-cancer therapy at least 2 weeks before getting NT-175.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Adam Schoenfeld’s office at 646-608-2091.
Protocol
25-078Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05877599ClinicalTrials.gov
-
Researchers want to find the best dose of ODM-212 to treat advanced solid tumors. The people in this study have solid tumors that have spread and cannot be cured with standard therapies. Examples include:
-
Researchers want to find the best dose of LY4066434 when given alone and with other drugs to treat solid tumors. The people in this study have cancer that has spread (advanced) or cannot be removed with surgery (inoperable). These include colorectal cancer, non-small cell lung cancer (NSCLC), pancreatic cancer, and other solid tumors.
- A Phase 1a Study of AVA6000 in People with Solid Tumors
Full Title A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6000, a Novel FAP-activated Doxorubicin Administered Intravenously in Patients with Locally Advanced or Metastatic Selected Solid Tumours
Purpose
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a “prodrug,” meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have inoperable or metastatic pancreatic, colorectal, non-small cell lung, head and neck, ovarian, breast, bladder, esophageal, prostate, or biliary tract cancer, soft tissue sarcoma, or cancer of unknown primary that continues to grow despite standard treatment.
- At least 4 weeks must pass between the completion of prior therapies and receipt of AVA6000.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
Contact
For more information and to ask about eligibility for this study, please contact the office of Dr. William Tap at 646-888-4163.
Protocol
22-428Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04969835ClinicalTrials.gov
-
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
-
After people receive chemotherapy for colon cancer, doctors may be able to detect tumor DNA in the blood ("circulating tumor DNA" or ctDNA). If there is ctDNA in the blood, a patient's cancer may be more likely to come back. It is standard for people with ctDNA in their blood to be monitored ("active surveillance"), but investigators would like to know if immediate treatment of these patients can prevent cancer recurrence.
- A Phase 1 Study of BBO-10203 in People With Advanced Solid Tumors
Full Title A Phase 1a/1b Study of the PI3Ka:RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors
Purpose
Researchers want to find the best dose of BBO-10203 to use in people with advanced solid tumors. The people in this study have one of these types of cancer that has spread (metastasized):
- Breast cancer that makes an excess amount of the HER2 protein.
- Breast cancer that is negative for HER2 but is fueled by estrogen and/or progesterone.
- Non-small cell lung cancer (NSCLC) with a mutation (change) in the KRAS gene.
- Colorectal cancer with a KRAS mutation.
BBO-10203 may slow or stop cancer growth by blocking the interaction between two proteins. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the cancers listed above that continues to grow despite treatment.
- Have recovered from the serious side effects of prior therapies before taking BBO-10203.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Komal Jhaveri’s office at 646-888-4226.
Protocol
25-038Phase
Phase I (phase 1)Disease Status
Newly Diagnosed & Relapsed/RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06625775ClinicalTrials.gov
-
Researchers are assessing petosemtamab given alone or with standard chemotherapy in people with advanced colorectal cancer. The people in this study have colorectal cancer that is inoperable (cannot be removed with surgery) or has metastasized (spread).
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.